Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cyclosporine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA known ✓ | P62937 | 5/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 11/20 | 0.67 |
| ▸ | PPP3CA | Q08209 | 5/20 | 0.67 |
| ▸ | FKBP1B | P68106 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.67 |
| ▸ | GMNN | O75496 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | RARB | P10826 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.67 |
| ▸ | TACR2 | P21452 | 1/20 | 0.67 |
| ▸ | PPIB | P23284 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12056960 | 0.82 | ABCB1 (0.76) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| SCHEMBL23110210 | 0.82 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL24239446 | 0.82 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL20475023 | 0.82 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL23192320 | 0.82 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL24239036 | 0.82 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL25083206 | 0.82 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL24239035 | 0.82 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL24224445 | 0.82 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| SCHEMBL23382247 | 0.82 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 60009 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075220-A | Contact lens for treating xerophthalmia and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | claimed |
| CN-122060112-A | Ophthalmic poly-nitroxide amphoteric ion nano-drug carrier, nano-preparation and application | 安徽中医药大学 | 2026-05-19 | — | — | CN | claimed |
| CN-122060073-A | Chimeric shuttle receptors | 深圳市湾岛细胞科技有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122036911-A | Human interleukin 2 variant and application thereof | 董明晖 | 2026-05-15 | — | — | CN | claimed |
| US-20260130991-A1 | HUMANIZED ANTI-CD40 ANTIBODIES AND USES THEREOF | PRIMATOPE THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | claimed |
| CN-122028914-A | Combination therapy for autoimmune disorders | 拜奥海芬治疗学有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-4649047-A | Ophthalmic treatment by topical administration of cyclosporin | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1987-03-10 | — | — | US | claimed |
| EP-0202017-A2 | Artificial microcompartmentalised structures and process for the manufacture thereof | Rafa Laboratories Ltd. (IL) | 1986-11-20 | — | — | EP | claimed |
| EP-0034567-B1 | A METHOD FOR THE TOTAL SYNTHESIS OF CYCLOSPORINS AND NOVEL CYCLOSPORINS | SANDOZ AG (CH) | 1984-11-07 | — | — | EP | claimed |
| EP-0056782-B1 | NOVEL CYCLOSPORINS | SANDOZ AG (CH) | 1984-08-01 | — | — | EP | claimed |
| US-4396542-A | Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production | SANDOZ LTD. (CH) | 1983-08-02 | — | — | US | claimed |
| US-4388307-A | CYCLOSPORIN WITH CARRIER OF VEGETABLE OIL, POLYALKYLENE GLYCOL TRANSESTERIFIED VEGETABLE OIL AND ETHANOL | SANDOZ LTD. (CH) | 1983-06-14 | — | — | US | claimed |
| EP-0056782-A1 | Novel cyclosporins | SANDOZ AG (CH) | 1982-07-28 | — | — | EP | claimed |
| US-4288431-A | CULTURING TOLYPLOCLADIUM, CATALYTIC HYDROGENATION, REARRANGEMENT; ANTIINFLAMMATORY, IMMUNOLOGY | SANDOZ LTD. (CH) | 1981-09-08 | — | — | US | claimed |
| EP-0034567-A2 | A method for the total synthesis of cyclosporins and novel cyclosporins | SANDOZ AG (CH) | 1981-08-26 | — | — | EP | claimed |
| US-4210581-A | CYCLOSPROINS USEFUL AS IMMUNOSUPPRESSIVES | SANDOZ LTD. (CH) | 1980-07-01 | — | — | US | claimed |